IndraLab

Statements

Ticagrelor inhibits NLRP3. 6 / 6
| 6
reach
"Ticagrelor inhibits the NLRP3 inflammasome to protect against inflammatory disease independent of the P2Y"
32523112
reach
"Importantly, oral administration of ticagrelor rapidly and strongly inhibited NLRP3 inflammasome activation in peripheral blood mononuclear cells from patients with acute coronary syndrome."
32523112
reach
"Both dapagliflozin and ticagrelor attenuated the progression of diabetic cardiomyopathy, the activation of the NLRP3 inflammasome, and fibrosis in BTBR mice with additive effects of the combination."
32335797
reach
"Ticagrelor, a P2Y12 receptor antagonist, and dapagliflozin, a sodium-glucose-cotransporter-2 inhibitor, suppress the activation of the NLRP3 inflammasome."
32335797
reach
"In this study, we systematically examined the effects of ticagrelor on the NLRP3 inflammasome and found that ticagrelor inhibits NLRP3 inflammasome activation in macrophages independent of its classic inhibitory effect on the P2Y 12 signaling pathway."
32523112
reach
"Both ticagrelor and rosuvastatin reduced postinfarction activation of NLRP3 inflammasome [136]."
34123416